Dicerna Pharmaceuticals Inc (DRNA)

3.12
NASDAQ : Health Care
Prev Close 3.12
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.69 / 15.93
Avg Volume 261.10K
Exchange NASDAQ
Shares Outstanding 20.73M
Market Cap 65.91M
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dicerna Appoints Martin Freed, M.D., To Board Of Directors

Dicerna Appoints Martin Freed, M.D., To Board Of Directors

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of Martin Freed, M.

Dicerna To Present At The Jefferies 2016 Healthcare Conference

Dicerna To Present At The Jefferies 2016 Healthcare Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Announces Dosing Of First Patient In Phase 1 Clinical Trial Of DCR-PH1 In Patients With Primary Hyperoxaluria Type 1 (PH1)

Dicerna Announces Dosing Of First Patient In Phase 1 Clinical Trial Of DCR-PH1 In Patients With Primary Hyperoxaluria Type 1 (PH1)

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1...

Dicerna Reports Potent Preclinical Activity With GalNAc-DsiRNA-EX Conjugates

Dicerna Reports Potent Preclinical Activity With GalNAc-DsiRNA-EX Conjugates

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today will present updated preclinical data demonstrating the potency of its proprietary...

Dicerna Reports First Quarter 2016 Financial And Operational Results

Dicerna Reports First Quarter 2016 Financial And Operational Results

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31, 2016.

Dicerna To Report First Quarter 2016 Financial Results And Host Conference Call On May 9, 2016

Dicerna To Report First Quarter 2016 Financial Results And Host Conference Call On May 9, 2016

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2016 financial results after market...

John B.

John B. "Jack" Green, Chief Financial Officer At Dicerna (Photo: Business Wire)

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B.

8 Biotech Stocks Under $10 Making Big Moves Higher

8 Biotech Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Dicerna Announces Fourth Quarter And Full Year 2015 Financial And Operational Results

Dicerna Announces Fourth Quarter And Full Year 2015 Financial And Operational Results

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced financial and operational results for the quarter and full year ended...

Dicerna To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Conference Call On March 10, 2016

Dicerna To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Conference Call On March 10, 2016

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, announced that the Company will release its fourth quarter and full year 2015 financial results after...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share look ready to break out and trade higher from current levels.

Dicerna To Present At Two March Conferences

Dicerna To Present At Two March Conferences

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M.

Dicerna Reports Progress With GalNAc-DsiRNA-EX-Conjugates

Dicerna Reports Progress With GalNAc-DsiRNA-EX-Conjugates

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNA interference (RNAi) therapeutics, today presented preclinical data suggesting the feasibility of its proprietary GalNAc-DsiRNA-EX-Conjugate...

Dicerna To Present At The 2016 Leerink Partners Global Healthcare Conference

Dicerna To Present At The 2016 Leerink Partners Global Healthcare Conference

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M.

Dicerna Pharmaceuticals Becomes Oversold (DRNA)

Dicerna Pharmaceuticals Becomes Oversold (DRNA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today...

Dicerna Begins Dosing In First Clinical Trial Of Therapy For Primary Hyperoxaluria Type 1 (PH1) In Healthy Volunteers

Dicerna Begins Dosing In First Clinical Trial Of Therapy For Primary Hyperoxaluria Type 1 (PH1) In Healthy Volunteers

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced it has initiated dosing in the first clinical trial of DCR-PH1, its investigational...

Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors

Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported continued progress in the clinical development of DCR-MYC, Dicerna's investigational...

Dicerna Announces Addition To NASDAQ Biotechnology Index

Dicerna Announces Addition To NASDAQ Biotechnology Index

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI),...

Dicerna Pharmaceuticals Appoints John

Dicerna Pharmaceuticals Appoints John "Jack" Green Interim Chief Financial Officer

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the appointment of John "Jack" Green as interim chief financial officer (CFO), effective January 1,...

Dicerna To Present At Two November Conferences

Dicerna To Present At Two November Conferences

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna Announces Third Quarter 2015 Financial And Operational Results

Dicerna Announces Third Quarter 2015 Financial And Operational Results

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based investigational therapeutics targeting rare inherited diseases involving the liver and for cancers that are...

Dicerna To Announce Third Quarter 2015 Financial Results And Host Conference Call On November 10, 2015

Dicerna To Announce Third Quarter 2015 Financial Results And Host Conference Call On November 10, 2015

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, announced...

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today...

Dicerna To Present Advances In Conjugate Delivery Technology At Leerink Partners Rare Disease Roundtable

Dicerna To Present Advances In Conjugate Delivery Technology At Leerink Partners Rare Disease Roundtable

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that Douglas M.

Dicerna To Present At The Leerink Partners Rare Disease Roundtable

Dicerna To Present At The Leerink Partners Rare Disease Roundtable

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that Douglas M.

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Dicerna Announces Second Quarter 2015 Financial And Operational Results

Dicerna Announces Second Quarter 2015 Financial And Operational Results

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today...